complementary actions may minimize adverse effects and reduce clinical outcomes by improving blood pressure control and organ protection.
7-10 ␤-Blockers are effective in hypertension treatment and reduce incidence of death and reinfarction in patients who have had a myocardial infarction (MI). 11 Along with diuretics, ␤-blockers became the standard of care for hypertensive CAD patients. 12 However, ␤-blockers may be less effective antihypertensive agents in older patients, who are also more likely to have CAD. 13, 14 The possibility that other antihypertensive regimens, particularly those containing calcium antagonists and/or angiotensin II active agents, might be as or more effective than ␤-blocker and/or diuretic regimens has not been convincingly demonstrated. 15, 16 Previous trials were performed predominantly in populations with low frequencies of CAD and used dihydropyridine calcium antagonists. 5, 6, 16, 17 A recent trial in high-risk hypertensive patients showed that a combination of an angiotensin II-receptor blocker and a diuretic was more effective than a combination of a ␤-blocker and a diuretic. 14 Heart rate-reducing nondihydropyridine calcium antagonists, on the other hand, have rarely been studied in large randomized hypertension trials, [18] [19] [20] [21] although verapamil appears to reduce the risk of death and reinfarction in acute CAD trials. 20 The combination of a nondihydropyridine calcium antagonist and an angiotensin-converting enzyme (ACE) inhibitor may provide better blood pressure control and organ protection than monotherapies. [22] [23] [24] [25] Many recent trials 8, 10, 14, 24, [26] [27] [28] [29] [30] indicate that drugs influencing the actions of angiotensin II can be beneficial in high-risk patients, but no hypertension trial has prospectively used these agents for CAD patients with diabetes, renal impairment, or heart failure.
We designed a randomized trial, the International Verapamil-Trandolapril Study (INVEST) , to compare outcomes in older hypertensive patients with CAD treated with a calcium antagonist strategy (CAS; verapamil sustained release [SR] ) or a non-calcium antagonist strategy (NCAS; atenolol). Because most older hypertensive patients require more than 1 agent to adequately control blood pressure, INVEST was intended to compare multidrug strategies rather than individual agents.
METHODS

Study Design
The INVEST design and methods have been published. 31 INVEST was an international, multicenter study with a prospective, randomized, open blinded end-point evaluation design 32 conducted according to principles of the Declaration of Helsinki. The institutional review boards and ethics committees at participating sites approved the protocol and patients provided written informed consent.
We tested the hypothesis that risk for adverse outcomes is equivalent to a verapamil SR-based regimen compared with an atenolol-based regimen. Clinically stable CAD patients with hypertension were randomly assigned to either verapamil SR or atenolol for blood pressure treatment according to the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) (target: systolic blood pressure [SBP] Ͻ140 and diastolic blood pressure [DBP] Ͻ90 mm Hg or SBP Ͻ130 mm Hg and DBP Ͻ85 mm Hg when diabetes or renal impairment is present). 9 Addition of trandolapril and/or hydrochlorothiazide was recommended when necessary to achieve blood pressure goals. Trandolapril also was recommended for patients with heart failure, diabetes, or renal insufficiency. Thus, this was not simply a comparison of verapamil SR with atenolol because it was anticipated that few patients would be treated with only those drugs. Ultimately, it was expected that most would be using the combination of verapamil SR plus trandolapril or atenolol plus hydrochlorothiazide.
Patient inclusion and exclusion criteria have been described previously. 31 Briefly, patients were eligible if they were aged 50 years or older and had documented CAD, with essential hypertension as defined by JNC VI 9 requiring drug therapy. Documented CAD was defined as any of the following: remote (Ն3 months prior to enrollment) confirmed MI, coronary angiogram with more than 50% narrowing of at least 1 major coronary artery, diagnosis of classic angina pectoris, or concordant abnormalities on 2 different types of signals (electrocardiograms, echocardiograms, and/or radionuclide scans) from stress tests provided that 2 different signals showed findings consistent for ischemia (eg, ST-segment depression and/or perfusion defects by radionuclide, and/or wall-motion abnormalities by echocardiogram or radionuclide). Patients with heart failure classes I through III were included. Patients taking ␤-blockers within 2 weeks of randomization or taking ␤-blockers for an MI that occurred in the previous 12 months were excluded to avoid withdrawal phenomena in patients randomized to the CAS group.
Following validity checks of eligibility data, an Internet-based management system automatically randomized each patient to a treatment strategy. The randomization scheme used a standard C routine and blocked by site using randomly permuted block sizes of 4 and 6. The randomization result was automatically stored in the central database as part of the patient's record and was also returned to the site investigator for electronic signature of strategy drugs in accordance with the protocol.
Interventions
FIGURE 1 outlines the protocolrecommended treatment schedule for each strategy to achieve JNC VI blood pressure targets. 9 The blood pressure target was determined from a mean of 2 sitting cuff blood pressure measurements as described in JNC VI. 9 Patients allocated to the CAS group were given 240 mg/d of verapamil SR while patients allocated to the NCAS group were given 50 mg/d of atenolol (step 1). If patients did not achieve target blood pressure, in step 2 the CAS group also could receive trandolapril (an ACE inhibitor) and the NCAS group also CALCIUM ANTAGONIST VS NON-CALCIUM ANTAGONIST could receive hydrochlorothiazide. The rationale for this was to maximize use of the combination of calcium antagonist and ACE inhibitor while minimizing diuretic use for the CAS group and maximizing use of the combination of ␤-blocker and diuretic for NCAS group. In step 3, doses were increased in both groups. In step 4, the CAS group also could receive hydrochlorothiazide and the NCAS group also could receive trandolapril. Trandolapril was recommended for all patients with renal impairment, diabetes, or heart failure. 9 If the dose was not well tolerated or the target blood pressure was not achieved, verapamil SR could be titrated to between 120 and 480 mg/d and atenolol could be titrated to between 25 and 200 mg/d. The recommended starting dose for trandolapril was 2 mg/d and it could be titrated to between 0.5 and 8 mg/d. For patients in the CAS group, a fixed combination was available for verapamil SR and trandolapril in doses of 180 mg/d and 2 mg/d, respectively; 240 mg/d and 1 mg/d; and 240 mg/d and 4 mg/d. The recommended starting dose for hydrochlorothiazide was 25 mg/d and it could be titrated between 12.5 and 100 mg/d. Doses greater than 25 mg of hydrochlorothiazide were provided to limit the need for nonstudy diuretics in patients with heart failure or edema. If the blood pressure goal was not achieved and adverse effects had not occurred, doses were titrated to those shown in Figure 1 before a patient was moved to the next step.
Additional nonstudy antihypertensive drugs, except ␤-blockers for CAS patients and calcium antagonists for NCAS patients, could be added when needed to reach blood pressure targets or minimize adverse effects. Patients were considered to have crossed over from their randomized treatment strategy if they received a ␤-blocker during the trial and were in the CAS group or received a calcium antagonist and were in the NCAS group. Standard of care nonpharmacological JNC VI guidelines 9 and secondary prevention according to the National Cholesterol Education Program were provided online to physicians, which could be printed and given to patients.
Patient Monitoring and Follow-up
Protocol visits were scheduled every 6 weeks for the first 6 months and then biannually until 2 years after the last patient was enrolled. Patients were assessed for response to treatment, occurrence of symptoms, treatment compliance, and adverse effects at each visit and at study close as detailed elsewhere.
31
Patient follow-up was complete when a final assessment form was received via the online data system or a death report was received. For all patients not completing the final assessment visit, lost to follow-up, or withdrawn, data were censored according to last visit date.
Study Outcomes
The primary outcome was the first occurrence of death (all-cause), nonfatal MI, or nonfatal stroke by intentionto-treat analysis. The MI and stroke definitions are detailed on the INVEST Web site.
33 These 3 components individually were the main secondary outcomes. Additional outcomes included time to most serious event (ranked from death as most serious, to MI, to stroke as least serious), cardiovascular death (definite or presumed), angina, cardiovascular hospitalizations, blood pressure control, cancer, Alzheimer disease, Parkinson disease, and gastrointestinal tract bleeding. 34 Shortly after the study started, new information became available on the potential for ACE inhibitors to prevent or delay the onset of diabetes. 8, 10 Accordingly, at the recommendation of the independent data safety and monitoring committee, new diagnosis of diabetes was 
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The drugs, order of addition, and recommended doses for each step of each strategy are summarized. Nonstudy antihypertensive drugs could be added to control blood pressure except for ␤-blockers in those assigned to the calcium antagonist strategy and calcium antagonists for those assigned to the non-calcium antagonist strategy. added as an outcome early in the recruitment phase of the study.
Outcomes such as death, MI, stroke, and cardiovascular hospitalization were reported within 24 hours using the online adverse event reporting system and then appropriate documentation was gathered. Adverse experiences were collected from responses to open, active questioning not restricted to those events known to be associated with the drugs taken. Three members of the events committee, masked to treatment assignment, confirmed all outcome events by reviewing documentation and other pertinent patient records. The data safety and monitoring committee reviewed efficacy and safety data at regular intervals throughout the trial.
Sample Size
It was decided a priori that a 20% difference in primary outcome between the treatment strategies would be clinically relevant 31 using the intention-totreat population. Therefore, the equivalence bound for the risk ratio was a confidence interval (CI) of 1.20 to 0.83. We assumed an annual primary outcome rate of no less than 2%, 31 an ␣ of .05 (2-sided), and 90% power when estimating the number of patients required. On this basis, a tentative sample size of 27000 patients was calculated, with an anticipated yearly drop-out rate of 5% to 10%. Because the enrollment period was longer than initially planned, patient-years of follow-up were greater than those used for initial power estimates. At the recommendation of the INVEST study biostatisticians and the data safety and monitoring committee, the steering committee reduced the sample size to 22000 patients.
Statistical Analysis
All of the main analyses were completed as specified in the protocol with the intention-to-treat population, including patients withdrawn or lost to follow-up censored at the time of the last visit (unless the patient was known to be dead based on death records). One planned interim analysis was performed in August 2001 and the prespecified stopping rules 33 were not met. The final significance level for the primary outcome, adjusted for the single interim analysis, was P = .04806 for a 2-sided test. For the secondary outcomes of death, nonfatal MI, and nonfatal stroke, a Bonferroni adjustment was made to the same P = .04806 significance level (P=.02 for each outcome). All other analyses are reported at the PϽ.05 significance level. KaplanMeier survival analysis was used to assess time to first event for the primary outcome and the main secondary outcomes. The primary outcome was analyzed both unadjusted and adjusted for 5 prespecified covariates: age, race, sex, previous MI, and prior heart failure. Standard relative risk (RR) estimates and 95% CIs were also calculated. 2 Analysis was used to compare CAS with NCAS on percentage occurrence of different outcomes. Cox proportional hazard models were used to evaluate potential interactions in the reported prespecified subgroup analyses (by baseline characteristic). All data were captured and stored in database tables (Version 7.1, Oracle, Redwood Shores, Calif). Data management and statistical analyses were performed using SAS statistical software (Version 8.2, SAS Institute Inc, Cary, NC). The database was maintained at the University of Florida, Division of Biostatistics, Gainesville.
RESULTS
Patient Enrollment
The pilot phase (30 selected sites) started in September 1997. Full-scale site recruitment and patient enrollment began in January 1998, and patient follow-up was completed on February 14, 2003. A total of 22 576 patients at 862 sites in 14 countries provided informed consent, satisfied administrative requirements, and completed randomization; 11 267 were assigned to the CAS group and 11309 to the NCAS group (FIGURE 2). A total of 594 patients had all assigned drugs withdrawn due to an adverse experience. A total of 568 patients failed to return for final assessment and did not appear in death searches (withdrawals or lost to follow-up). These latter patients were censored at the time of their last visit. Mean follow-up was 2.7 years (range, 1 day to 5.4 years) in each strategy. A total of 30829 patient-years were accumulated in the CAS group and 31006 patient-years in the NCAS group.
Baseline Characteristics
At baseline, patient characteristics were well-balanced ( *Values expressed as number (percentage) unless otherwise indicated. Percentages may not equal 100 due to rounding. †History of or currently taking antidiabetic or lipid-lowering medications. ‡History of or currently have elevated serum creatinine level but less than 4 mg/dL (Ͻ354 µmol/L). §Patients with a history of skin, prostate, and other cancers with long survival expectancy were not excluded. Insulin and/or oral hypoglycemics. ¶Data for women only (n = 5850 for calcium antagonist strategy and n = 5920 for non-calcium antagonist strategy).
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©2003 American Medical Association. All rights reserved. mm Hg in the in the NCAS group (P = .26). A reduction of 90% of the maximum achieved in SBP and 100% in DBP occurred in the first 6 months of treatment; the reductions were maintained throughout the trial. Mean resting heart rate at 24 months was significantly lower (PϽ.001) in NCAS patients (69.2/min) compared with CAS patients (72.8/min). Kaplan-Meier analysis (unadjusted) of time to first primary outcome event demonstrated no difference comparing the CAS group with the NCAS group for a primary outcome (Figure 4 ; RR, 0.98 [95% CI, 0.90-1.06]). A sensitivity analysis in which the 568 patients who were lost to follow-up or withdrew were all presumed to have died produced an RR of 1.00 (95% CI, 0.94-1.08). When adjusted for the prespecified covariates of age, race, sex, previous MI, and previous heart failure, the CAS and NCAS groups were not different (hazard ratio [HR], 0.98; 95% CI, 0.91-1.07; P=.69). Other outcomes were also similar in frequency between strategies ( Figure 5 ). Time to death (all cause) did not differ between treatment groups (P=.72), nor did time to nonfatal MI (P=.95), or time to nonfatal stroke (P=.33). Time to the most serious event also did not differ between treatment groups (P=.58). Fatal and nonfatal MI occurred in 452 CAS patients (4.01%) and 441 NCAS patients (3.90%) (RR, 1.03; 95% CI, 0.90-1.17). Fatal and nonfatal stroke occurred in 176 CAS patients (1.56%) and 201 NCAS patients (1.78%) (RR, 0.88; 95% CI, 0.72-1.07). Subgroup analyses by baseline characteristics showed con- Abbreviations: ACE, angiotensin-converting enzyme; CAS, calcium antagonist strategy.
Outcomes
*According to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (see text). †Included clonidine, methyldopa, and moxonidine. ‡Patients taking ␤-blockers within 2 weeks of randomization or taking ␤-blockers for an MI that occurred in the previous 12 months were excluded to avoid withdrawal phenomena in patients randomized to the CAS group.
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sistency for the primary outcome in both high-and low-risk subgroups (FIGURE 6). Of particular note were the similar event rates for each strategy among patients with prior MI as well as those with prior coronary revascularization. The exception was patients with prior heart failure, for which those assigned to the NCAS strategy appeared to have fewer events (P = .03 for interaction). Also important was the marked difference in the event rate of 14.3% (913/6400) for those with diabetes compared with 8.4% (1356/16176) for those without diabetes. The effect of the treatment strategies using an overall SBP control goal of less than 140 mm Hg and DBP control goal of less than 90 mm Hg was similar. A total of 5625 patients (71.7%) in the CAS group and 5553 (70.7%) in the NCAS group achieved overall blood pressure control at 24 months (P=.18). Based on JNC VI blood pressure goals, SBP control was achieved by 65.0% of CAS patients (n=5093) compared with 64.0% of NCAS patients (n = 5025) (P=.23); DBP control was achieved by 88.5% of CAS patients (n=6937) compared with 88.1% of NCAS patients (n = 6914) (P =.46). At baseline, angina was reported in 66.2% of CAS patients (n=7463) compared with 67.0% of NCAS patients 
Adverse Experiences
Both drug combinations were generally well tolerated in each treatment group. Cancer was reported in 192 patients (1.70%) in the CAS group compared with 186 patients (1.64%) in the NCAS group (P = .73). Alzheimer disease, gastrointestinal tract bleeding, and Parkinson disease were reported in 1% or less of patients in each group and incidence did not differ between groups. Patients in the CAS group reported constipation and 11 267 8558  3659  7758  8639  1458  5721  796  7842  7850 Time, mo Level, mm Hg
Diastolic Blood Pressure
There were no significant differences in systolic or diastolic blood pressure. cough more frequently than patients in the NCAS group, while NCAS patients had more dyspnea, lightheadedness, symptomatic bradycardia, and wheezing (Table 5) .
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COMMENT
We tested the hypothesis that treatment of hypertensive CAD patients with either a verapamil SR-based strategy (CAS group) or a ␤-blocker-based strategy (atenolol; NCAS group) would result in equivalent clinical outcomes. Our findings demonstrated that these treatment strategies were equivalent in the prevention of the outcome of allcause mortality, nonfatal MI, or nonfatal stroke. Furthermore, similar results were observed comparing the treatment strategies for all-cause mortality, cardiovascular death, cardiovascular hospitalization, and blood pressure control. Significant differences were observed between strategies that favored the verapamil SR plus trandolapril strategy (CAS group) for lower angina frequency and new diagnoses of diabetes. There was a significant interaction between treatment group and prior heart failure, suggesting that those randomized to the atenolol plus hydrochlorothiazide strategy (NCAS group) had better outcomes than those randomized to the verapamil SR plus trandolapril strategy (CAS group). Both strategies were well tolerated.
INVEST is the first, to our knowledge, large randomized, prospective trial to focus on CAD patients with hypertension and to follow JNC VI guidelines, 9 which recommend use of an ACE inhibitor for special populations and lower blood pressure goals than other guidelines. It is important to note that this was not simply a comparison of verapamil SR with atenolol because it was anticipated that few patients would be treated with only those drugs. At study end, most were taking the combination of verapamil SR plus trandolapril (CAS group) or atenolol plus hydrochlorothiazide (NCAS group). Also, the study population included a high percentage of elderly, female, nonwhite, and diabetic patients. Thus, the results reported herein should be clinically applicable.
Although other trials 3, 5, 16, 21 have investigated use of calcium antagonists in hypertensive patients, the frequency of CAD in these trials was too low to reach any relevant conclusions.
For example, the Nordic Diltiazem (NORDIL) study demonstrated equivalence between diltiazem and diuretics and/or ␤-blockers for cardiovascular morbidity and mortality and showed a reduction in incidence of fatal and nonfatal stroke in the diltiazem group, but only a small proportion of those patients (4.5%; n = 496) had coronary heart disease. 21 Results from several hypertension trials, including LIFE 14 and ALLHAT, 16 have been confounded by differences in achieved blood pressure level, which influences outcomes. In our study, the reductions and achieved levels for SBP and DBP were similar in both treatment groups. Most INVEST patients achieved JNC VI goals for blood pressure control. These findings in patients with CAD extend those from LIFE 14 and ALLHAT, 16 demonstrating that even lower blood pressure targets are achievable with more aggressive management. However, ALLHAT neither tested a ␤-blocker arm nor used an angiotensin II active agent for organ protection for patients with diabetes, renal impairment, or heart failure. Thus, INVEST results complement ALLHAT by including a ␤-blocker-based strategy plus organ protection in an elderly population with CAD. The INVEST data also confirm and extend the suggestions of others 7, 35 that monotherapy is not necessarily sufficient for optimal treatment of hypertension.
Overall, adverse experiences reported were minimal and similar in frequency between treatment strategies. Previous articles 17, 36, 37 have suggested that some calcium antagonists (principally short-acting dihydropyridines) may be associated with an increased risk of cancer, gastrointestinal tract bleeding, and all-cause mortality. Results of ALLHAT, 16 STOP-2, 5 and INVEST have not confirmed these suggestions. The difference in crossover rates may reflect the consequences of adverse experiences (dyspnea, lightheadedness, symptomatic bradycardia, and wheezing) associated with the combination of atenolol plus hydrochlorothiazide (NCAS group) compared with adverse experiences (constipation and CALCIUM ANTAGONIST VS NON-CALCIUM ANTAGONIST cough) associated with the combination of verapamil SR plus trandolapril (CAS group). The possibility that the higher crossover rate in the atenololbased strategy is related to previous intolerance or physician bias against ␤-blockers cannot be excluded, particularly because patients recently taking ␤-blockers were excluded from the trial. Another possibility is that the differing drug components of CAS (verapamil SR plus trandolapril) or NCAS (atenolol plus hydrochlorothiazide) could have conferred advantages in addition to blood pressure control. The combination of verapamil SR plus trandolapril could result in fewer metabolic complications, as was observed with reduction of new diagnoses of diabetes. The NCAS might have been expected to have advantages in patients with a prior MI and prior coronary revascularization; however, the results observed were similar with both strategies. Our outcome data for patients with prior heart failure, on the other hand, concur with recent trials documenting benefits of ␤-blockers when added to diuretics and ACE inhibitors, 38-40 although not all patients in those trials had hypertension. In light of the results reported herein, management of hypertension must focus on the risk profile of the patient and overall treatment regimen rather than a single drug.
There are some limitations to our study. We used blood pressure goals in accordance with JNC VI; however, JNC VII 7 and epidemiological data 41 indicate that CHD risk increases with SBP level higher than 115 mm Hg so it could be argued that even lower blood pressure targets may be reasonable. More than half the patients required 3 or more antihypertensive drugs to achieve blood pressure control. Better blood pressure control might have been possible if we had included a fourth drug in each of the specified treatment strategies. The large sample size resulted in a statistically significant difference in angina frequency comparing CAS with NCAS, but this difference may not be clinically significant. The decline in angina prevalence and frequency from entry (only 2% underwent revascularization) is clinically important. This, at least in part, is likely due to the decline in both SBP and heart rate. Lastly, although the new diabetes analysis was not planned before the trial started, we added this outcome early in the recruitment phase. Our findings suggest potential clinical implications that require confirmation. Other analyses of INVEST baseline data indicate that Hispanic ethnicity, heart failure, US residency, hypercholesterolemia, left ventricular hypertrophy, stroke and transient ischemic attack, prior coronary revascularization, and body mass index are linked to risk of developing diabetes. 42 In our preliminary analyses herein, administration of trandolapril appeared to confer some protection, as suggested in previous studies of ACE inhibitors. 8, 10, 16, 43 Hydrochlorothiazide was associated with a nonsignificantly increased risk of developing diabetes, which is also consistent with previous studies (usually a thiazide diuretic with a ␤-blocker). 14, 16, 44 Further analyses are required to better understand the complex interactions among drug, dose, and demographic factors. Patients' potassium levels were not collected in this study, so the role that hypokalemia may have played in precipitating hyperglycemia cannot be determined.
In conclusion, our results indicate that lower targets for blood pressure control can be achieved in most hypertensive patients with CAD using a multidrug strategy that includes administration of ACE inhibitors to patients with heart failure, diabetes, or renal impairment. The clinical equivalence of the CAS and NCAS groups in prevention of death, MI, or stroke supports the use of either strategy in clinically stable patients with CAD who require blood pressure control. The decision regarding which drug classes to use in specific CAD patients should be based on additional factors including adverse experiences, history of heart failure, diabetes risk, and the physician's best judgment. The possibility of delaying the emergence of a diabetes diagnosis with a CAS compared with an NCAS requires further investigation. 
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